Search Results
Your search for ,foR matches 33012 pages
Showing 21201 - 21250AbbVie and Lurie Cancer Center, Johns Hopkins Announce 5-Year Oncology Research Collaborations
The global biopharmaceutical company AbbVie has announced collaborations with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Johns Hopkins University School of Medicine. These 5-year partnerships to advance cancer research and discovery in oncology will focus on...
Exploring Practical Strategies for Cancer Care in Low-Resource Settings
One of the featured “Big Debates” at the 2016 World Cancer Congress in Paris addressed this question: Are scarce resources best applied to prevention rather than treatment? Many experts do not see prevention vs treatment in such stark terms or even as a realistic scenario. It’s a false dichotomy,...
Co-occurrence of Cancer and Cognitive Impairment in Older Adults
The prevalence of both cancer and cognitive impairment increases with age.1-3 Based upon Surveillance, Epidemiology, and End Results (SEER)-Medicare studies, it is estimated that 3% to 7% of patients with cancer aged ≥ 65 also suffer from dementia, although the true prevalence of dementia in this...
The Best of SIO
The following five abstracts were chosen as the best submitted studies presented at this year’s International Conference of the Society for Integrative Oncology (SIO). They represent a diverse group of integrative therapies and interventions in the care of patients with cancer, including an...
Advancing the Global Impact of Integrative Oncology
The 13th International Conference of the Society of Integrative Oncology (SIO) held in Miami, Florida, in November, drew its largest audience yet, with nearly 400 clinicians, researchers, patients, and patient advocates in integrative oncology care from 25 countries in attendance with large...
Expert Point of View: Carlos L. Arteaga, MD
Press conference moderator Carlos L. Arteaga, MD, of Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, said that buparlisib will probably not be clinically useful, partly because it crosses the blood-brain barrier , thus causing mood disorders, and is not an ideal phosphoinositide 3-kinase...
Buparlisib Phase III Findings: Glass Half Empty or Half Full?
The pan-phosphoinositide 3-kinase (PI3K) inhibitor buparlisib combined with fulvestrant (Faslodex) prolonged progression-free survival compared with placebo and fulvestrant in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer previously treated with an...
Expert Point of View: Myles Brown, MD, Carlos L. Arteaga, MD, and Eric Winer, MD
Myles Brown, MD, Director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute, Boston, suggested the failure of the endocrine therapy to increase the pathologic complete response rates “may be related to the fact that the aromatase inhibitor was not the optimal...
Pathologic Complete Response Not Boosted by Addition of Estrogen Deprivation to Chemotherapy and Dual HER2 Blockade
The addition of estrogen deprivation to neoadjuvant chemotherapy and HER2 blockade did not enhance the achievement of pathologic complete responses in women with early-stage breast cancer, according to the results of the NRG Oncology/NSABP B-52 trial reported at the 2016 San Antonio Breast Cancer...
Expert Point of View: Carlos L. Arteaga, MD
Press conference moderator Carlos L. Arteaga, MD, said: “This drug is not necessarily the same as palbociclib [Ibrance] or ribociclib. There are subtle differences among these three [cyclin-dependent kinase (CDK) 4/6] inhibitors. The tissue analysis provides us with an enormous opportunity to...
Abemaciclib Plus Anastrozole: Promising Signals Reported in Phase II Study of Early Breast Cancer
As neoadjuvant therapy, abemaciclib alone or in combination with anastrozole achieved strong signals of anticancer activity in postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer in the neoMONARCH phase II study.1 Abemaciclib alone or in combination with anastrozole...
Expert Point of View: Leif Ellisen, MD, PhD
Results of this trial have been anticipated for a long time. Women were enrolled between 2000 and 2008,” said Leif Ellisen, MD, PhD, Program Director of Breast Medical Oncology at Massachusetts General Hospital Cancer Center in Boston. Regarding the survival advantage in triple-negative...
BRCA Status Does Not Seem to Affect Survival Outcomes in Young Women With Early Breast Cancer
Young women who carry the BRCA1 and/or BRCA2 mutation and develop breast cancer seem to have similar survival compared with young women who have BRCA-negative breast cancer. However, women with BRCA-positive triple-negative breast cancer have an 11% survival advantage compared with those with...
Genomic Landscape of Metastatic Breast Cancer Differs From That of Primary Breast Cancer
Researchers working on whole-exome and transciptome sequencing of endocrine-resistant estrogen receptor–positive metastatic breast cancer have shown that the mutational landscape differs from that of estrogen receptor–positive primary breast cancer, and these differences have the potential to...
Expert Point of View: Virginia Kaklamani, MD
How can the results of this trial be applied to clinical practice? Press conference moderator, Virginia Kaklamani, MD, of the University of Texas Health Science Center in San Antonio, said: “The landscape has changed. Now we treat postmenopausal hormone receptor–positive, HER2-negative metastatic...
Fulvestrant Plus Everolimus: New Second-Line Option for Postmenopausal Metastatic Breast Cancer
The addition of everolimus (Afinitor) to fulvestrant (Faslodex) doubled progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer resistant to aromatase inhibitor therapy compared with fulvestrant plus placebo, according to the...
Oncology Organizations Applaud Passage of the 21st Century Cures Act
On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, attended the White House signing ceremony ...
Gilberto de Lima Lopes, Jr, MD, MBA, FAMS, Named New Editor-in-Chief of ASCO’s Journal of Global Oncology
ASCO announced that Gilberto de Lima Lopes, Jr, MD, MBA, FAMS, will become Editor-in-Chief of the Society’s Journal of Global Oncology (JGO) in early 2017. Dr. Lopes will direct the editorial scope of JGO, an online-only, open-access journal addressing the unique challenges of cancer care and...
FDA Permits Marketing of New Tissue Expander for Women Undergoing Breast Reconstruction Following Mastectomy
On December 21, the U.S. Food and Drug Administration (FDA) allowed marketing of a new tissue-expander system for soft-tissue expansion in two-stage breast reconstruction following mastectomy and in the treatment of underdeveloped breasts and soft-tissue deformities. A patient uses a dose...
Expert Point of View: Armand Keating, MD
“This study shows that a great deal of innovation can come from existing knowledge. The 7+3 regimen has been around since I was an intern,” admitted Armand Keating, MD, of the University of Toronto and Princess Margaret Hospital, Toronto, Ontario, Canada. “Using the liposomal formulation of...
CPX-351 Improves Survival Post Transplant in Older High-Risk Patients With Acute Myeloid Leukemia
Induction therapy with the experimental chemotherapy called CPX-351—a liposomal formulation of cytarabine and daunorubicin—outperformed standard “7+3” cytarabine plus daunorubicin by extending survival in older high-risk patients with acute myeloid leukemia (AML) who subsequently underwent...
Expert Point of View: Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, MS, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Center in Ohio, commented on vadastuximab talirine in newly diagnosed acute myeloid leukemia (AML). He noted that the drug is similar to gemtuzumab ozogamicin, another antibody-drug conjugate that...
American Cancer Society Welcomes Three New Members and Newly Elected Officers to Board of Directors
The American Cancer Society announced the election of three new members—Amit Kumar, PhD, Joseph M. Naylor, and William D. Novelli—to the 2017 American Cancer Society Board of Directors. In addition, the new key officer leadership positions were announced, which include Arnold M. Baskies,...
Vadastuximab Talirine Shows Early Promise in Newly Diagnosed Acute Myeloid Leukemia
The investigational CD33-directed antibody-drug conjugate vadastuximab talirine yielded high overall and complete response rates when combined with standard “7+3” chemotherapy for patients newly diagnosed with acute myeloid leukemia.1 Results from this phase Ib study were presented at the 2016...
A Lesson From David
The following essay by Jeremy K. Hon, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. As physicians, ...
2017 Oncology Meetings
JANUARY 2017 2017 Oncologic Emergency Medicine ConferenceJanuary 12-13 • Houston, Texas For more information: www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/oncologic-emergency-medicine-conference.html 2017 Highlights of ASH in North...
Expert Point of View: Lawrence Kaplan, MD
“This study is important because R-CHOP [rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone] has been the standard of care for many years. CHOP, the chemotherapy backbone, has withstood challenges from more aggressive regimens in the past. The excellent clinical outcomes observed ...
Monica M. Bertagnolli, MD, Elected ASCO President for 2018–2019 Term
Monica M. Bertagnolli, MD, a long-time ASCO member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally, three new members were elected to...
St. Jude Names Ellis J. Neufeld, MD, PhD, Clinical Director, Physician-in-Chief, and Executive Vice President
Ellis J. Neufeld, MD, PhD, has been appointed Clinical Director, Physician-in-Chief, and Executive Vice President of St. Jude Children’s Research Hospital. Dr. Neufeld’s appointment will begin in March 2017. In this role, Dr. Neufeld will oversee the organization’s academic clinical departments...
Weighing the Benefits and Risks of Medical Marijuana
Despite the fact that 28 states and the District of Columbia have enacted laws to permit the use of cannabis and cannabinoid-based drugs to treat medical conditions, including cancer and symptoms from its treatment, federal law prohibits physicians from prescribing marijuana to their patients,...
Dose-Adjusted EPOCH-R No Better Than R-CHOP in Diffuse Large B-Cell Lymphoma
Long-awaited results of the Cancer and Leukemia Group B (CALGB)/Alliance 50303 trial were a disappointment to many hematologists/oncologists at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition. The study failed to show that dose-adjusted EPOCH-R (etoposide,...
Accelerating Progress in the Treatment of Glioblastoma Multiforme
W.K. Alfred Yung, MD, has wanted a career in medicine since he was a high-school student and has spent nearly 4 decades fulfilling that dream, specifically in the research and treatment of one of the deadliest cancers, malignant brain tumor, especially glioblastoma multiforme, the most common...
Expert Point of View: Brad S. Kahl, MD
Speaking about the GALLIUM study in the ASH News Daily, Brad S. Kahl, MD, of Washington University School of Medicine, St. Louis, commented, “It is a potentially practice-changing study that clearly shows an 8% absolute improvement in progression-free survival at 2 years for the patients getting...
Obinutuzumab Prolongs Disease-Free Survival vs Rituximab in Follicular Lymphoma
Induction and maintenance therapies with obinutuzumab (Gazyva) were superior to rituximab (Rituxan) induction and maintenance in patients with untreated follicular lymphoma, according to results of the phase III GALLIUM study presented at the Plenary Session during the 58th American Society of...
Updated ASTRO Guideline Expands Pool of Suitable Candidates for Accelerated Partial-Breast Irradiation
On November 17, 2016, the American Society for Radiation Oncology (ASTRO) issued an updated clinical practice statement for accelerated partial-breast irradiation for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients may benefit from...
Mutational Characteristics of Chemotherapy-Treated Bladder Urothelial Neoplasms
Radical cystectomy with urinary diversion is the standard of care for muscle invasive bladder cancer.1 Meta-analyses of prospective data have shown a 5% overall survival benefit at 5 years for those receiving neoadjuvant systemic chemotherapy prior to cystectomy.2,3 We currently know of two...
Study Identifies Factors in Clonal Evolution of Chemotherapy-Resistant Urothelial Carcinoma
In a study reported in Nature Genetics, Bishoy M. Faltas, MD, of Weill Cornell Medicine, and colleagues identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma.1 As stated by the investigators: “Chemotherapy-resistant urothelial carcinoma has no uniformly curative...
Confirmation or Transformation? The Case of Palbociclib in Hormone Receptor–Positive Metastatic Breast Cancer
Women with hormone receptor–positive metastatic breast cancer are witnessing an unprecedented time of success in the battle against their disease. Just in the past 12 months, a number of prospective, randomized, phase III studies were reported, with positive results indicating the value of...
Addition of Palbociclib to Letrozole in Previously Untreated Advanced Estrogen Receptor–Positive, HER2-Negative Breast Cancer
In the phase III PALOMA-2 trial reported in The New England Journal of Medicine, Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues found that the addition of palbociclib (Ibrance) to letrozole significantly improved...
Cancer.Net Resource Helps Patients Manage Cancer Costs
Help your patients manage the financial impact of a cancer diagnosis with Cancer.Net’s Managing the Cost of Cancer Care booklet. This booklet provides information on key financial categories for cancer care; an easy-to-understand explanation of health insurance coverage; information about the...
ASCO and ONS Release Updated Chemotherapy Administration Standards to Include Pediatric Oncology Care
ASCO and the Oncology Nursing Society (ONS) have updated their chemotherapy administration safety standards to include pediatric oncology care. The updated standards can be found in the Journal of Oncology Practice.1 In 2009, ASCO and the Oncology Nursing Society published the initial set of...
ASCO and New Presidential Administration, Congress: Advancing Patient-Focused Cancer Policies
The results of every Presidential election offer both challenges and opportunities for ASCO’s advocacy efforts. ASCO’s mission is to help practices and patients with cancer thrive—in every setting and in every community. Through each administration and Congress, the Society works closely with...
Expert Point of View: Sergio A. Giralt, MD
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, New York, and the Melvin Berlin Family Chair in Multiple Myeloma, commented on the findings of the StaMINA trial for The ASCO Post. He said the results of the largest randomized U.S....
Single Autotransplant Not Enhanced by Additional Interventions in Multiple Myeloma
Additional interventions following upfront autologous stem cell transplant in multiple myeloma did not further improve progression-free or overall survival over transplant alone in a multicenter study presented as a late-breaking abstract at the 2016 American Society of Hematology (ASH) Annual...
Nancy Thomas, MD, PhD, Named Chair of Dermatology at University of North Carolina
University of North Carolina (UNC) Lineberger Comprehensive Cancer Center member Nancy Thomas, MD, PhD, has been named Chair of the Department of Dermatology, effective January 1. She assumes the role from Luis Diaz, MD, who is stepping down from the position after serving as Chair for 16 years....
Lawrence N. Shulman, MD, FACP, Named Chair of American College of Surgeons’ Commission on Cancer
Lawrence N. Shulman, MD, FACP, Professor of Medicine in the Perelman School of Medicine and Deputy Director for Clinical Services of the Abramson Cancer Center at the University of Pennsylvania, has been named the new Chair of the Commission on Cancer of the American College of Surgeons. The...
Conquer Cancer Foundation Matching Gift Challenge Offers Chance to Double Your Impact
The Conquer Cancer Foundation has an incredible opportunity for you to make an amazing impact! An anonymous donor is offering a Matching Gift Challenge, which will double the value of every gift we receive by December 31—dollar for dollar—up to $64,000! This amount is enough to fund one of our...
Individuals Honored as 2016 MPN Heroes
Eight individuals were honored at the 2016 MPN Heroes celebration held on the eve of the American Society of Hematology’s (ASH) Annual Meeting & Exposition in San Diego. The MPN Hero award is given by Cure magazine in recognition of an individual’s commitment to helping patients with...
Expert Point of View: Amir T. Fathi, MD
“In the past few years, there has been increased reporting of other, less traditional, response criteria in acute myeloid leukemia (AML), including morphologic leukemia-free state, partial response, and complete remission [or complete response] with incomplete recovery. There is some concern that...
Women in Oncology: Breaking Down Barriers and Looking to the Future
There has been no better time than the present for women in the field of oncology: Women at all stages of their careers are finding more opportunities and avenues to excel. At the time of the last ASCO workforce survey, women made up 28.4% of the oncologist workforce, and that proportion is rising...
